PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.
NCT02362620
·
clinicaltrials.gov ↗
UNKNOWN
Status
402
Enrollment
OTHER
Sponsor class
Conditions
Advanced Prostate Cancer
Cabazitaxel
Docetaxel
Sponsor
Centro Nacional de Investigaciones Oncologicas CARLOS III